The relationship between glaucoma and dry eye illness as well as the function of preservatives in glaucoma drugs

Marianus Deepak Lakra; Puspa Kumari; Sarojini Murmu

doi:10.18203/2320-6012.ijrms20231798

Authors

Marianus Deepak Lakra Department of Eye, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India
Puspa Kumari Department of Eye, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India
Sarojini Murmu Department of Eye, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20231798

Keywords:

Topical medications, Glaucoma, Ocular surface disease, Dry eye frequency, Antiglaucoma therapy

Abstract

Background: The aim of the study was to evaluate the incidence of xerophthalmia in individuals with glaucoma by administering a topical regimen of antiglaucoma medication containing timolol and dorzolamide and to determine the frequency of ocular surface abnormalities among individuals with glaucoma who are undergoing treatment with topical antiglaucoma medications.

Methods: The study included a total of 75 participants of both genders. A total of 50 ocular units from 25 subjects under medication with two or more antiglaucoma agents for a period of six months were subjected to examination.

Results: The study compared tear breakage time, Schirmer's test-1, and corneal staining score between the glaucoma cases and control groups. The mean values for tear breakage time were 9.44±2.76 seconds and 11.8±1.88 sec in the glaucoma and control group respectively (p=0.001). The mean values for Schirmer's test-1 were 7.63±2.64 mm and 12.86±1.93 mm in the glaucoma and control group respectively (p=0.001). The mean values for corneal staining score were 5.7±2.33 and 1.1±0.58 in the glaucoma and control group (p=0.001) respectively.

Conclusions: The prevalence of ocular surface disease and dry eye is higher among individuals undergoing antiglaucoma therapy. The application of glaucoma medication in the form of topical treatment has been associated with the development of dry eye syndrome and has been observed to affect the stability of the tear film.

Metrics

Metrics Loading ...

References

Pflugfelder SC, Baudouin C. Challenges in the clinical measurement of ocular surface disease in glaucoma patients. Clin Ophthalmol. 2011;5:1575-83.

McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ. Current management of glaucoma and the need for complete therapy. Am J Manag Care. 2008;14(1):S20-7.

Koffuor GA, Ababio-Danso B, Gyanfosu L, Amoateng P. The efficacy of NHIS-listed anti-glaucoma drugs in the management of primary open-angle glaucoma. J Med Biomed Sci. 2012;1(2):50-8.

Amponsah CT, Amoaku WM, Ofosu-Amaah S, Ewusi RK, Idirisuriya-Khair R, Nyatepe-Coo E, Adu-Darko M. Prevalence of glaucoma in an African population. Eye (Lond). 2004;18(5):491-7.

Budenz DL, Barton K, Whiteside-de Vos J, Schiffman J, Bandi J, Nolan W, et al. Prevalence of glaucoma in an urban West African population: the Tema Eye Survey. JAMA Ophthalmol. 2013;131(5):651-8.

Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106(3):556-63.

Barisic F, Krolo I, Popovic-Suic S, Sesar I, MarijaSimicPrskalo M, Mandic Z. Prevalence of ocular surface disease in patients with glaucoma using topical antiglaucoma medications. J Clin Exp Ophthalmol 2014;5:334.

Arici MK, Arici DS, Topalkara A, Güler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exp Ophthalmol. 2000;28(2):113-7.

Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1):1-9.

Guedes RA, Guedes VM, Freitas SM, Chaoubah A. Quality of life of medically versus surgically treated glaucoma patients. J Glaucoma. 2013;22(5):369-73.

Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18(5):205-15.

Wilson WS, Duncan AJ, Jay JL. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J Ophthalmol. 1975;59(11):667-9.

The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75-92.

Versura P, Profazio V, Campos EC. Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases. Curr Eye Res. 2010;35(7):553-64.

Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci. 2006;47(10):4309-15.

Lemp MA, Bron AJ, Baudouin C, Benítez Del Castillo JM, Geffen D, Tauber J, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 2011;151(5):792-8.

Sullivan BD, Whitmer D, Nichols KK, Tomlinson A, Foulks GN, Geerling G, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci. 201;51(12):6125-30.

Li DQ, Chen Z, Song XJ, Luo L, Pflugfelder SC. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2004;45(12):4302-11.

Labbé A, Terry O, Brasnu E, Van Went C, Baudouin C. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea. 2012;31(9):994-9.

Janulevičienė I, Derkač I, Grybauskiene L, Paulauskaitė R, Gromnickaite R, Kuzmienė L. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol. 2012;6:103-9.

Arici MK, Arici DS, Topalkara A, Güler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exp Ophthalmol. 2000;28(2):113-7.

Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992;99(7):1082-8.

Lee AJ, Lee J, Saw SM, Gazzard G, Koh D, Widjaja D, Tan DT. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol. 2000;86(12):1347-51.

Gomes B, Turiel PR, Marques FP, Bernardo FP, Safady MV, Portes AL, et al. Signs and symptoms of ocular surface disease in patients on topical intraocular pressure-lowering therapy. Arq Bras Oftalmol. 2013;76(5):282-7.

Zulfiqar N, Ansari MSA, Nafees K, Nawaz R, Shaheen M. Dry eye in glaucoma patients using topical anti-glaucoma therapy. Pak J Ophthalmol 2020;36(1):43-7.

Kovačević S, Čanović S, Pavičić AD, Kolega MŠ, Bašić JK. Ocular surface changes in glaucoma patients related to topical medications. Coll Antropol. 2015;39(1):47-9.

Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418-23.

Saini M, Vanathi M, Dada T, Agarwal T, Dhiman R, Khokhar S. Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy. Int J Ophthalmol. 2017;10(6):931-8.

Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350-5.